NASDAQ:GLTO - Galecto Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 149.55 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.61
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Galecto Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLTO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$14.00
▲ +149.55% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $14.00, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 149.55% upside from the last price of $5.61.

Buy

The current consensus among 3 investment analysts is to buy stock in Galecto.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2021Credit Suisse GroupLower Price TargetOutperform$29.00 ➝ $12.00High
i
3/16/2021SVB LeerinkLower Price TargetOutperform$27.00 ➝ $16.00High
i
Rating by T. Smith at SVB Leerink LLC
11/23/2020SVB LeerinkInitiated CoverageOutperform$27.00High
i
Rating by T. Smith at SVB Leerink LLC
11/23/2020Credit Suisse GroupInitiated CoverageOutperform$29.00High
i
11/23/2020Bank of AmericaInitiated CoverageBuyHigh
i
(Data available from 6/14/2016 forward)
Galecto logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $5.61
$5.35
$5.95

50 Day Range

MA: $5.49
$4.63
$8.00

52 Week Range

Now: $5.61
$4.50
$17.99

Volume

2,967,048 shs

Average Volume

297,770 shs

Market Capitalization

$141.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Galecto?

The following sell-side analysts have issued reports on Galecto in the last twelve months: Bank of America Co., Credit Suisse Group AG, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for GLTO.

What is the current price target for Galecto?

2 Wall Street analysts have set twelve-month price targets for Galecto in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 149.6%. SVB Leerink LLC has the highest price target set, predicting GLTO will reach $16.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $12.00 for Galecto in the next year.
View the latest price targets for GLTO.

What is the current consensus analyst rating for Galecto?

Galecto currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLTO will outperform the market and that investors should add to their positions of Galecto.
View the latest ratings for GLTO.

What other companies compete with Galecto?

How do I contact Galecto's investor relations team?

Galecto's physical mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company's listed phone number is 45 70 70 52 10. The official website for Galecto is galecto.com.